ATE311196T1 - Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga - Google Patents

Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga

Info

Publication number
ATE311196T1
ATE311196T1 AT98923763T AT98923763T ATE311196T1 AT E311196 T1 ATE311196 T1 AT E311196T1 AT 98923763 T AT98923763 T AT 98923763T AT 98923763 T AT98923763 T AT 98923763T AT E311196 T1 ATE311196 T1 AT E311196T1
Authority
AT
Austria
Prior art keywords
controlled release
analogues
gnrh
compositions suitable
hormone gnrh
Prior art date
Application number
AT98923763T
Other languages
English (en)
Inventor
Patrick J Burns
John W Gibson
Arthur J Tipton
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26668592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE311196(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Durect Corp filed Critical Durect Corp
Application granted granted Critical
Publication of ATE311196T1 publication Critical patent/ATE311196T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
AT98923763T 1997-05-28 1998-05-26 Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga ATE311196T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4778997P 1997-05-28 1997-05-28
US09/001,123 US6051558A (en) 1997-05-28 1997-12-30 Compositions suitable for controlled release of the hormone GnRH and its analogs
PCT/US1998/010668 WO1998053837A1 (en) 1997-05-28 1998-05-26 COMPOSITIONS SUITABLE FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS

Publications (1)

Publication Number Publication Date
ATE311196T1 true ATE311196T1 (de) 2005-12-15

Family

ID=26668592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98923763T ATE311196T1 (de) 1997-05-28 1998-05-26 Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga

Country Status (10)

Country Link
US (1) US6051558A (de)
EP (1) EP1017411B1 (de)
AT (1) ATE311196T1 (de)
AU (1) AU743086C (de)
BR (1) BR9809189A (de)
CA (1) CA2291087C (de)
DE (1) DE69832631T2 (de)
ES (1) ES2255162T3 (de)
NZ (1) NZ501219A (de)
WO (1) WO1998053837A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6028057A (en) * 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
AU5025300A (en) * 1999-06-18 2001-01-09 Southern Biosystems, Inc. Compositions for controlled release of the hormone gnrh and its analogs
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US6992065B2 (en) * 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
US20040115236A1 (en) * 2000-10-06 2004-06-17 Chan Tai Wah Devices and methods for management of inflammation
ATE303156T1 (de) * 2000-10-30 2005-09-15 Univ Zuerich Verwendung von gnrh-analogue zur behandlung der harninkontinenz
CA2438208A1 (en) * 2001-02-07 2002-08-15 Durect Corporation Devices and methods for management of bone density
CA2448218C (en) * 2001-06-21 2012-05-29 Genentech, Inc. Sustained release formulation
WO2003080629A2 (en) 2002-02-25 2003-10-02 Guilford Pharmaceuticals, Inc. Phosphorus-containing compounds with polymeric chains, and methods of making and using the same
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ES2350689T3 (es) 2002-12-13 2011-01-26 Durect Corporation Sistema de suministro de fármacos oral que comprende materiales vehículo líquidos de alta viscosidad.
CA2540838C (en) * 2003-10-03 2014-12-16 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
WO2005067889A1 (en) * 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
WO2006033948A2 (en) * 2004-09-17 2006-03-30 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as saib
CA2590239A1 (en) * 2004-12-23 2006-07-06 Durect Corporation Controlled release compositions
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20080286375A1 (en) * 2005-11-15 2008-11-20 Amorepacific Corporation Method for Preparing Sustained-Release Microparticles Comprising Sucrose Acetate Isobutyrate
US20090036384A1 (en) * 2005-12-02 2009-02-05 Parnell Laboratories (Aust) Pty Limited Increasing pregnancy rates
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
WO2008066642A2 (en) 2006-11-03 2008-06-05 Durect Corporation Transdermal delivery systems comprising bupivacaine
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CA2695697A1 (en) 2007-08-07 2009-02-12 Advanced Technologies And Regenerative Medicine, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
JP2011506318A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 経口医薬製剤
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
EP2244679A4 (de) 2008-02-08 2013-10-09 Qps Llc Nicht-polymer-zusammensetzungen zur kontrollierten arzneimittelabgabe
US20090202481A1 (en) 2008-02-08 2009-08-13 Qps Llc Composition for Sustained Release Delivery of Proteins or Peptides
EP2276458A1 (de) * 2008-04-14 2011-01-26 Advanced Technologies and Regenerative Medicine, LLC Flüssige gepufferte gdf-5-formulierungen
WO2009145690A1 (en) 2008-05-29 2009-12-03 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
DK2421545T3 (en) 2009-04-23 2018-03-12 Jbs United Animal Health Ii Llc PROCEDURE AND COMPOSITION TO SYNCHRONIZE THE TIME OF INSEMINATION.
AR082266A1 (es) 2011-05-13 2012-11-28 Univ Nac Del Litoral Microparticula inyectable de liberacion controlada
MX367876B (es) 2012-11-28 2019-09-10 United Ah Ii Llc Método para sincronización del tiempo de inseminación en cerdas jóvenes.
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
CA2945179A1 (en) * 2014-05-16 2015-11-19 Michael S. Mcgrath Methods and compositions for treatment of macrophage-related disorders
CL2016000217A1 (es) * 2016-01-27 2016-07-01 Farmacologia En Aquacultura Veterinaria Fav S A Nueva composición veterinaria inyectable para la sincronización del desove en peces
CN111202837B (zh) * 2018-11-22 2022-02-08 中国农业大学 一种用于控制马属动物排卵的制剂及控制排卵的方法
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
CN113350275B (zh) * 2021-06-19 2022-09-06 江西农业大学 一种烯丙孕素缓释注射液及其制备方法和应用
CA3228691A1 (en) 2021-08-25 2023-03-02 Nathan Wells Methods for reproductive management of sheep and goats

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
NO139560C (no) * 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
DE2451841A1 (de) * 1973-11-01 1975-05-07 Wellcome Found Biologisch aktive amide, verfahren zu ihrer herstellung und ihre verwendung
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
WO1991016929A1 (en) * 1990-05-10 1991-11-14 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
IT1240643B (it) * 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
YU87892A (sh) * 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
US5545408A (en) * 1991-10-21 1996-08-13 Peptide Technology Limited Biocompatible implant for the timing of ovulation in mares
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
PT1006935E (pt) * 1995-06-07 2005-06-30 Durect Corp Sistema de entrega controlada liquido de alta viscosidade
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system

Also Published As

Publication number Publication date
EP1017411A4 (de) 2002-09-04
ES2255162T3 (es) 2006-06-16
DE69832631T2 (de) 2006-08-10
AU743086B2 (en) 2002-01-17
NZ501219A (en) 2002-03-01
CA2291087C (en) 2009-12-29
WO1998053837A1 (en) 1998-12-03
EP1017411B1 (de) 2005-11-30
CA2291087A1 (en) 1998-12-03
DE69832631D1 (de) 2006-01-05
US6051558A (en) 2000-04-18
AU743086C (en) 2004-07-15
AU7598098A (en) 1998-12-30
BR9809189A (pt) 2002-12-03
EP1017411A1 (de) 2000-07-12

Similar Documents

Publication Publication Date Title
ATE311196T1 (de) Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga
DK1006935T3 (da) Styret afgivelsessystem med en væske med höj viskositet
AU5911101A (en) Sustained release formulations
IL117144A0 (en) Pharmaceutical compositions containing nucleic acids
MX9500072A (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
HU900108D0 (en) Composition of controlled active ingredient delivery, operating by hydrogel
GEP20022709B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
BR9812313A (pt) Sistema de liberação controlada de lìquido de viscosidade elevada como um dispositivo
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
EP0398619A3 (de) Stabilisierte, den epidermalen Wachstumsfaktor enthaltende Mittel
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
DE69101291D1 (de) Zusammensetzung zur kontrollierten Abgabe von Medikamenten.
MY101784A (en) Novel pharmacological compounds
MY101919A (en) Pharmaceutical compositions
EP0299654A3 (en) Composition and use
IL91047A0 (en) Pharmaceutical compositions containing a zinc complex
MX9300586A (es) Nuevos fragmentos de hormona paratiroidea proceso para su preparacion y composiciones farmaceuticas que los contienen.
BR9912706A (pt) Composições farmacêuticas contendo ibuprofeno e domperidona
ATE546461T1 (de) Gnrh analog von nicht-säugertieren und verwendung zur regulierung der fruchtbarkeit und der schwangerschaft
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
ZA87332B (en) Compositions containing fixed combinations
EP1074264A4 (de) Inhibitoren für die gefässneubildung
MX9802105A (es) Composiciones estabilizadas suavizadoras de telas.
JO1999B1 (en) Isotopes of the hormone 'LH-RH' have their uses and the chemical compounds they contain
NZ320211A (en) Lipid alcohols as new immunosuppressive and antiviral drugs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties